Developer docs
API playgroundTry for free, no card

Search company profiles

Bertis

Full company profile

uuid000248w

Namestring
Bertis
Legal namestring
BERTIS Inc
Websiteurl
bertis.com
Company typeenum
Private
Founded yearint
2014
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeongnam, South Korea
HQ citystring
Seongnam
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
proteomics diagnostics services, cancer early detection tests, mass spectrometry analysis, precision medicine biomarkers, pan-omics research services
Industry5 codes
PRIMARYHLAGANAB
Proteomics & Mass Spectrometry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing
SECONDARYHLAAAMAA
Biomarker Discovery & Validation (omics, assay feasibility, clinical validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical Laboratories621511
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Testing Laboratories8734
Product category
Molecular Diagnostics
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1MASTOCHECK Diagnostic Tests
TypeTransaction Fee
Description

Sales of breast cancer early detection blood tests through hospitals, medical checkup centers, and diagnostic laboratories. Revenue generated per test through distribution agreements with healthcare providers in Korea and internationally.

bertis.com
2PASS (Pan-omics Analysis Service & Solution)
TypeProfessional Services
Description

B2B proteomics analysis services provided to pharmaceutical companies and biotech firms for biomarker discovery, drug development research, and companion diagnostics. Revenue generated through project-based contracts and analysis service fees.

bertis.com
3Diagnostic Pipeline Products
TypeTransaction Fee
Description

Future revenue expected from PANCCHECK (pancreatic cancer), OVACHECK (ovarian cancer), and next-generation Mastocheck2 products currently under development and clinical trials.

bertis.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
Pricing details1 tier
1MASTOCHECK breast cancer screening test
ModelOtherBilling cadencePay-as-you-go
Notes

Pricing not publicly disclosed; test available at hospitals and medical checkup centers

bertis.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1MASTOCHECK
Description

World's first proteomics-based breast cancer early detection blood test

bertis.com
+3 more records
Core offering1 text field

Bertis is a proteomics-based molecular diagnostics company that commercializes the world's first proteomics-based breast cancer early detection blood test (MASTOCHECK®) and provides pan-omics analysis services (PASS) to pharmaceutical and biotech companies for drug discovery and biomarker research. Its proprietary quantitative proteomics platform leverages mass spectrometry and AI to identify disease-related protein panels for cancer diagnostics and translational research.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 92% accuracy for 0-2 stage breast cancer diagnosis using 3-biomarker algorithm
+4 more records
Product and service2 records
1MASTOCHECK®
CategoryCancer Diagnostics
Description

Proteomics-based blood test for early detection of breast cancer, requiring only 1 ml of blood with no radiation exposure. Approved for stage 0-2 breast cancer diagnosis at 92% accuracy. Effective for women with dense breast tissue, young women aged 20-30, and pregnant women. Distributed through 550+ hospitals and medical checkup centers in Korea and through channel partners across Southeast Asia.

2PASS (Pan-omics Analysis Service & Solution)
CategoryProteomics Research Services
Description

Customer-customized proteomics analysis service for pharmaceutical companies and biotech firms, providing comprehensive proteome and phosphoproteome profiling for biomarker discovery, drug mechanism studies, and companion diagnostics. Utilizes Orbitrap Astral mass spectrometer with proprietary COFFER fractionation technology identifying over 10,000 proteins per sample.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership15 partners
1Fraunhofer IZI
Strategic tierSignificantTypeStrategic or Co-development Partner
Description

October 2019 MOU for global joint R&D on proteomics-based early diagnosis solutions. Collaboration includes comparing tumor marker expression between European and Asian patients, serum tumor marker investigation, early diagnosis prediction algorithms, and therapeutic peptide development.

bertis.com
2MedicalIP
Strategic tierSignificantTypeStrategic or Co-development Partner
Description

March 2021 MOU for developing bio-dual compound AI platform using medical imaging data and quantitative proteomics. Aims to predict and prevent diseases through integrated analysis of genomic, proteomic, and medical imaging data (CT, MRI, X-ray).

bertis.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

April 2021 MOU for blood plasma proteomics analysis research. Collaboration on sex and age-based blood protein profiling and protein biomarker discovery for personalized health monitoring.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

December 2021 MOU for proteomics-based cancer diagnosis and treatment technology R&D. Includes proteomics biomarker research using tissue and blood samples, and clinical trial collaboration for next-generation cancer diagnostics and therapeutics.

5Vanderbilt University Medical Center (VUMC)
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

March 2026 joint research contract for AI-based drug target discovery. Bertis applies its AI-based drug target discovery platform to VUMC's spatial omics research, combining DEEP-find™ with VUMC's spatial omics tissue analysis. Focus on HER2-low tumors initially, expanding to various cancer types.

bertis.com
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

July 2025 supply agreement with Singapore's largest clinical diagnostic laboratory. Strengthens Singapore testing infrastructure and enables expansion to Indonesia, Malaysia, Thailand, Vietnam, Philippines, Australia, and Hong Kong (7 countries).

Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

September 2022 supply agreement with Singapore's largest private healthcare group. MASTOCHECK deployed through Raffles Breast Centre, Raffles Health Screeners, and 30+ medical institutions. Future expansion planned to China, Japan, Cambodia, Vietnam.

Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

January 2025 supply agreement for MASTOCHECK sales and marketing in Thailand and Philippines. LifeStrands is a genomics subsidiary of Pathology Asia Group leveraging hospital networks across 5 countries.

9Cosmax
Strategic tierSignificantTypeStrategic or Co-development Partner
Description

April 2025 MOU for skin proteomics analysis research cooperation. Collaboration includes skin protein analysis technology development, joint biomarker panel development, and cosmetics ingredient formulation and commercialization.

bertis.com
Strategic tierSignificantTypeStrategic or Co-development Partner
Description

July 2021 MOU for developing next-generation breast cancer cell therapy using proteogenomic analysis technology. Bertis analyzes breast cancer subtypes using its proteogenomic technology, combined with E&Cell's cell therapy development capabilities for subtype-specific new drug candidate discovery.

11Rockit Genomics
Strategic tierStrategicTypeTechnology or Integration
Description

August 2024 MOU for single-cell proteomics and genomics analysis service collaboration. Bertis provides single-cell proteomics analysis services while Rockit Genomics offers single-cell genomic sequencing, enabling multi-omics analysis services and joint technology development.

bertis.com
12Ulsan National Institute of Science and Technology
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

September 2024 joint participation in Ministry of Science and ICT 'Spatial Proteomics Multi-omics Analysis Technology Development' project. 4.5-year project with 9 billion KRW research budget involving 6 institutions. Bertis develops LC-MS analysis conditions for single cells and spatial proteomics-specific preprocessing materials.

bertis.com
13MetaBioTech
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Co-research partner in spatial proteomics technology development project. Developing protein peptidization materials and source technology, aiming to establish global-first analysis platform from tissue separation to diagnosis.

bertis.com
14Korea Basic Science Institute
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Partner in spatial proteomics multi-omics technology development project led by Ulsan National Institute of Science and Technology.

bertis.com
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Partner in spatial proteomics multi-omics technology development project, contributing to database construction and AI software development for cancer-type specific biomarkers.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US proteomics company operating the SomaScan platform for large-scale protein measurement, serving pharma R&D and clinical diagnostics applications. Direct peer in protein biomarker discovery and clinical proteomics services.

TypeDirect peer
Description

US cancer genomics/proteomics company providing molecular diagnostics and biomarker analysis for pharma and clinical customers. Direct peer in deep molecular profiling services for oncology.

TypeBroad incumbent
Description

US diagnostics leader (Cologuard for colorectal cancer screening, Oncotype DX). Broad incumbent in non-invasive cancer screening diagnostics with overlapping technology platform approach.

TypeDirect peer
Description

US liquid biopsy leader (Guardant360, Guardant Shield) using blood-based molecular diagnostics for cancer detection and monitoring. Direct peer in blood-based cancer screening diagnostics.

TypeDirect peer
Description

Sweden-based proteomics company offering high-throughput protein biomarker discovery platforms (PEA technology) used widely in pharma research and clinical studies. Closely comparable in customer base (pharma/biotech) and biomarker analytical services, though with a different technology foundation.

TypeBroad incumbent
Description

US clinical cancer diagnostics laboratory offering oncology-focused testing services across multiple modalities. Broader incumbent in cancer diagnostics with overlapping biomarker discovery and clinical testing services.

TypeRegional player
Description

Korea-based molecular diagnostics company specializing in multiplex PCR technologies for infectious disease and oncology. Regional peer from the same Korean diagnostics ecosystem with comparable hospital distribution model.

TypeRegional player
Description

Korea-based genomics and precision medicine company providing sequencing services and molecular diagnostics. Regional peer operating in Korea with similar B2B services model and Asia-focused expansion.

TypeDirect peer
Description

US-based proteomics company using mass spectrometry for deep, unbiased proteomic profiling. Direct peer in the proteomics platform business serving pharma/biotech researchers, similar to Bertis's PASS offering.

10GRAIL
TypeDirect peer
Description

US multi-cancer early detection company (Galleri test) developing blood-based screening for multiple cancers. Direct peer in early-stage, blood-based multi-cancer screening.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks2 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers11 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bertis

Molecular Diagnosticsbertis.com

Bertis firmographics

Firmographics
Name
Bertis
Legal name
BERTIS Inc
Website
https://bertis.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Bertis industry classification

Industry
Product category
Molecular Diagnostics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Testing Laboratories (8734)
akta.pro industry
PRIMARYHLAGANAB
Proteomics & Mass Spectrometry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing
SECONDARYHLAAAMAA
Biomarker Discovery & Validation (omics, assay feasibility, clinical validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

  • Proteomics diagnostics services
  • Cancer early detection tests
  • Mass spectrometry analysis
  • Precision medicine biomarkers
  • Pan-omics research services

Where Bertis is headquartered

Location

Headquarters

HQ city
Seongnam
HQ country
South Korea
HQ region
Asia

Offices3 records

Markets served

Bertis business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. MASTOCHECK Diagnostic Tests: Sales of breast cancer early detection blood tests through hospitals, medical checkup centers, and diagnostic laboratories. Revenue generated per test through distribution agreements with healthcare providers in Korea and internationally.
  2. PASS (Pan-omics Analysis Service & Solution): B2B proteomics analysis services provided to pharmaceutical companies and biotech firms for biomarker discovery, drug development research, and companion diagnostics. Revenue generated through project-based contracts and analysis service fees.
  3. Diagnostic Pipeline Products: Future revenue expected from PANCCHECK (pancreatic cancer), OVACHECK (ovarian cancer), and next-generation Mastocheck2 products currently under development and clinical trials.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goMASTOCHECK breast cancer screening test

Go-to-market motion3 records

Distribution channels5 records

Marketing channels7 records

Bertis product offering

Product offering

Core offering

Bertis is a proteomics-based molecular diagnostics company that commercializes the world's first proteomics-based breast cancer early detection blood test (MASTOCHECK®) and provides pan-omics analysis services (PASS) to pharmaceutical and biotech companies for drug discovery and biomarker research. Its proprietary quantitative proteomics platform leverages mass spectrometry and AI to identify disease-related protein panels for cancer diagnostics and translational research.

Differentiator

Problem solved

Functional benefit

Brands

  • MASTOCHECK: World's first proteomics-based breast cancer early detection blood test
  • PASS
  • DEEP-find
  • CHECK series

Products and services

  • MASTOCHECK® Proteomics-based blood test for early detection of breast cancer, requiring only 1 ml of blood with no radiation exposure. Approved for stage 0-2 breast cancer diagnosis at 92% accuracy. Effective for women with dense breast tissue, young women aged 20-30, and pregnant women. Distributed through 550+ hospitals and medical checkup centers in Korea and through channel partners across Southeast Asia.
  • PASS (Pan-omics Analysis Service & Solution) Customer-customized proteomics analysis service for pharmaceutical companies and biotech firms, providing comprehensive proteome and phosphoproteome profiling for biomarker discovery, drug mechanism studies, and companion diagnostics. Utilizes Orbitrap Astral mass spectrometer with proprietary COFFER fractionation technology identifying over 10,000 proteins per sample.

Quantifiable outcome

  • 92% accuracy for 0-2 stage breast cancer diagnosis using 3-biomarker algorithm
  • +4 more outcomes

Companies that use Bertis

Customer profile

Named customers11 records

Segments3 records

Ideal customer profiles1 record

Bertis technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature8 records

Bertis partnerships and signals

Strategic signal

Partnerships

15 partnerships are on record, tiered significant, core, flagship, major and strategic.

  • Fraunhofer IZIsignificantStrategic or Co-development PartnerOctober 2019 MOU for global joint R&D on proteomics-based early diagnosis solutions. Collaboration includes comparing tumor marker expression between European and Asian patients, serum tumor marker investigation, early diagnosis prediction algorithms, and therapeutic peptide development.
  • MedicalIPsignificantStrategic or Co-development PartnerMarch 2021 MOU for developing bio-dual compound AI platform using medical imaging data and quantitative proteomics. Aims to predict and prevent diseases through integrated analysis of genomic, proteomic, and medical imaging data (CT, MRI, X-ray).
  • Seoul National University Bundang HospitalcoreStrategic or Co-development PartnerApril 2021 MOU for blood plasma proteomics analysis research. Collaboration on sex and age-based blood protein profiling and protein biomarker discovery for personalized health monitoring.
  • National Cancer Center KoreacoreStrategic or Co-development PartnerDecember 2021 MOU for proteomics-based cancer diagnosis and treatment technology R&D. Includes proteomics biomarker research using tissue and blood samples, and clinical trial collaboration for next-generation cancer diagnostics and therapeutics.
  • Vanderbilt University Medical Center (VUMC)flagshipStrategic or Co-development PartnerMarch 2026 joint research contract for AI-based drug target discovery. Bertis applies its AI-based drug target discovery platform to VUMC's spatial omics research, combining DEEP-find™ with VUMC's spatial omics tissue analysis. Focus on HER2-low tumors initially, expanding to various cancer types.
  • Innoquest Diagnostics / Pathology Asia GroupcoreChannel Partner/ Reseller/ DistributorJuly 2025 supply agreement with Singapore's largest clinical diagnostic laboratory. Strengthens Singapore testing infrastructure and enables expansion to Indonesia, Malaysia, Thailand, Vietnam, Philippines, Australia, and Hong Kong (7 countries).
  • Raffles Medical GroupmajorChannel Partner/ Reseller/ DistributorSeptember 2022 supply agreement with Singapore's largest private healthcare group. MASTOCHECK deployed through Raffles Breast Centre, Raffles Health Screeners, and 30+ medical institutions. Future expansion planned to China, Japan, Cambodia, Vietnam.
  • LifeStrandsmajorChannel Partner/ Reseller/ DistributorJanuary 2025 supply agreement for MASTOCHECK sales and marketing in Thailand and Philippines. LifeStrands is a genomics subsidiary of Pathology Asia Group leveraging hospital networks across 5 countries.
  • CosmaxsignificantStrategic or Co-development PartnerApril 2025 MOU for skin proteomics analysis research cooperation. Collaboration includes skin protein analysis technology development, joint biomarker panel development, and cosmetics ingredient formulation and commercialization.
  • E&CellsignificantStrategic or Co-development PartnerJuly 2021 MOU for developing next-generation breast cancer cell therapy using proteogenomic analysis technology. Bertis analyzes breast cancer subtypes using its proteogenomic technology, combined with E&Cell's cell therapy development capabilities for subtype-specific new drug candidate discovery.
  • Rockit GenomicsstrategicTechnology or IntegrationAugust 2024 MOU for single-cell proteomics and genomics analysis service collaboration. Bertis provides single-cell proteomics analysis services while Rockit Genomics offers single-cell genomic sequencing, enabling multi-omics analysis services and joint technology development.
  • Ulsan National Institute of Science and TechnologystrategicStrategic or Co-development PartnerSeptember 2024 joint participation in Ministry of Science and ICT 'Spatial Proteomics Multi-omics Analysis Technology Development' project. 4.5-year project with 9 billion KRW research budget involving 6 institutions. Bertis develops LC-MS analysis conditions for single cells and spatial proteomics-specific preprocessing materials.
  • MetaBioTechstrategicStrategic or Co-development PartnerCo-research partner in spatial proteomics technology development project. Developing protein peptidization materials and source technology, aiming to establish global-first analysis platform from tissue separation to diagnosis.
  • Korea Basic Science InstitutestrategicStrategic or Co-development PartnerPartner in spatial proteomics multi-omics technology development project led by Ulsan National Institute of Science and Technology.
  • Bundang CHA Hospital Future Medicine InstitutestrategicStrategic or Co-development PartnerPartner in spatial proteomics multi-omics technology development project, contributing to database construction and AI software development for cancer-type specific biomarkers.

Scale indicators8 records

Recent moves8 records

Expansion highlights7 records

Bertis competitors and assessment

Company assessment

Direct peers

  • SomaLogic: US proteomics company operating the SomaScan platform for large-scale protein measurement, serving pharma R&D and clinical diagnostics applications. Direct peer in protein biomarker discovery and clinical proteomics services.
  • Personalis: US cancer genomics/proteomics company providing molecular diagnostics and biomarker analysis for pharma and clinical customers. Direct peer in deep molecular profiling services for oncology.
  • Guardant Health: US liquid biopsy leader (Guardant360, Guardant Shield) using blood-based molecular diagnostics for cancer detection and monitoring. Direct peer in blood-based cancer screening diagnostics.
  • Olink Holding: Sweden-based proteomics company offering high-throughput protein biomarker discovery platforms (PEA technology) used widely in pharma research and clinical studies. Closely comparable in customer base (pharma/biotech) and biomarker analytical services, though with a different technology foundation.
  • Seer: US-based proteomics company using mass spectrometry for deep, unbiased proteomic profiling. Direct peer in the proteomics platform business serving pharma/biotech researchers, similar to Bertis's PASS offering.
  • GRAIL: US multi-cancer early detection company (Galleri test) developing blood-based screening for multiple cancers. Direct peer in early-stage, blood-based multi-cancer screening.

Broad incumbents

  • Exact Sciences: US diagnostics leader (Cologuard for colorectal cancer screening, Oncotype DX). Broad incumbent in non-invasive cancer screening diagnostics with overlapping technology platform approach.
  • NeoGenomics: US clinical cancer diagnostics laboratory offering oncology-focused testing services across multiple modalities. Broader incumbent in cancer diagnostics with overlapping biomarker discovery and clinical testing services.

Regional players

  • Seegene: Korea-based molecular diagnostics company specializing in multiplex PCR technologies for infectious disease and oncology. Regional peer from the same Korean diagnostics ecosystem with comparable hospital distribution model.
  • Macrogen: Korea-based genomics and precision medicine company providing sequencing services and molecular diagnostics. Regional peer operating in Korea with similar B2B services model and Asia-focused expansion.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks2 records

Key highlights7 records

Customer concentration

Bertis social profiles

Digital presence

Bertis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bertis leadership team

Management profile

Number of profiles

Profiles8 records

Bertis subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Bertis funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bertis M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bertis

What does Bertis do?

Bertis is a proteomics-based molecular diagnostics company that commercializes the world's first proteomics-based breast cancer early detection blood test (MASTOCHECK®) and provides pan-omics analysis services (PASS) to pharmaceutical and biotech companies for drug discovery and biomarker research. Its proprietary quantitative proteomics platform leverages mass spectrometry and AI to identify disease-related protein panels for cancer diagnostics and translational research.

Is Bertis a public or private company?

Bertis is a private company. It is classified as venture growth investor backed and is currently operating.

When was Bertis founded?

Bertis was founded in 2014. It employs 11 to 50 people.

Where is Bertis based?

Bertis is headquartered in Seongnam, South Korea, in the Asia region.

How does Bertis make money?

Three revenue lines are on record. MASTOCHECK Diagnostic Tests are the primary driver. The others are PASS (Pan-omics Analysis Service & Solution) and diagnostic Pipeline Products.

Who are Bertis's main competitors?

Direct peers on record are SomaLogic, Personalis, Guardant Health, Olink Holding, Seer and GRAIL. Broad incumbents are Exact Sciences and NeoGenomics. Regional players are Seegene and Macrogen.

Does Bertis have an API?

No public API is recorded for Bertis.

What industry is Bertis in?

Bertis's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAGANAB, Proteomics & Mass Spectrometry Services, with a secondary code of HLAGADAG, Proteomics & Biomarker Analytical Testing. Its NAICS code is 541714 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
KBRMSD Korea, KHIDI select 4 AI healthcare startups for global mentoringMSD Korea and the Korea Health Industry Development Institute held an AI healthcare innovation summit in Seoul, selecting four Korean digital health startups—Beamworks, BERTIS, Mediwhale, and Persely—for global mentoring and commercialization support. The three panel-selected winners will receive a combined 90 million won ($62,000) in funding, while all eight pitching companies become eligible for additional KHIDI support including preferential consideration under its global biohealth expansion program. MSD Korea has discussed potential partnerships with 51 Korean companies this year as part of efforts to strengthen Korea's healthcare and biopharmaceutical competitiveness.EIN PresswireBertis Enables Hanmi's Breakthrough Obesity Drug Mechanism Discovery with Advanced Proteomics ExpertiseBertis, a South Korea-based proteomics company, announced that its advanced proteomics platform PASS played a key role in uncovering the molecular mechanism of Hanmi Pharmaceutical's novel obesity drug HM17321, with findings presented at the EASD 2025 conference in Vienna. The analysis successfully identified over 10,000 proteins from skeletal muscle samples—a 20% improvement over previous studies—revealing HM17321's dual mechanism of promoting muscle growth while selectively reducing fat. The global proteomics market is projected to grow from USD 36.8 billion in 2023 to USD 72.9 billion by 2028, highlighting the increasing role of proteomics in drug development.ThemonodistCosmax and Bertis join forces to redefine anti-aging skincare with skin proteome cosmeticsKorean cosmetic manufacturing giant Cosmax announced on April 15, 2025 a strategic partnership with proteomics technology company Bertis to develop customized skin proteome cosmetics targeting individual factors of skin aging. The collaboration will use Bertis' peptide library of over 7,000 peptides combined with Cosmax's tape-stripping technique for non-invasive skin sample collection to build a database categorizing skin proteins by aging factors. The companies aim to create personalized skincare solutions and diagnostic software that could revolutionize the anti-aging cosmetics market.Business Wire BlogBertis Announces Research Results of AI-based Disease Diagnosis Model in the World’s Largest Academic Event in ProteomicsBertis presented research results of an AI-based disease diagnosis model at HUPO 2022, which can detect ovarian and pancreatic cancer from proteomic mass spectrometry data with over 95% accuracy. The model was trained on 156 ovarian and 116 pancreatic cancer blood samples. Bertis plans to expedite R&D to improve accuracy and speed for major diseases.PR NewswireCancer Biomarkers Market to Exceed US$ 34 Billion by 2032 as Need for Early Detection in Lung & Prostate Cancer RisesFact.MR released a market research report projecting the global cancer biomarkers market to grow from US$ 9.1 billion in 2021 to over US$ 34 billion by 2032, driven by increasing cancer prevalence and demand for early detection. The market is expected to expand at a 12% CAGR during 2022–2032, with breast cancer holding the largest market share while prostate cancer sees growing demand for PSA testing. Key players including F. Hoffmann-La Roche, Thermo Fisher Scientific, and Qiagen N.V. are investing in R&D to develop novel diagnostic products, with companies like Bertis and Oxford Cancer Biomarkers recently launching new biomarker and pharmacogenomics tests.